Prevalence of adverse effects of COVID19 vaccines among a sample of Iranian healthcare workers; a comparison between the three available vaccines in Iran

Abstract

Objectives:Describing what to expect after the first and second dose of vaccination will increase the public confidence. This study aimed to describe the short-term side effects after receiving the first, the second, or both doses of Sputnik V, Oxford-AstraZeneca, and Sinopharm vaccines in personnel and students of shahid Beheshti dentistry school. Methods: A cohort project has been conducting at the dental faculty since June 2020. This article is a cross-sectional study as a section of the cohort project. Dental faculty began its campaign to vaccinate the personnel on April 2021, with the Sputnik V and Oxford-AstraZeneca and Sinopharm. An employed operator phoned each one by one after 48 hours of vaccination. She asked them about any experienced symptoms after receiving each dose. The reported symptoms were coded and categorized. Results: The most common symptoms in AstraZeneca's first dose were fever followed by Myalgia. After the second dose, the frequency of all symptoms had been reduced significantly. After the first dose of Sputnik V, the most common symptoms were Myalgia followed by fever. The frequency of fever and pain at the injection site increased significantly after the second dose (P < 0.001). In the Sinopharm group, all symptoms occurred whit a low percentage. The most common symptoms were again, Myalgia and pain at the injection site. Conclusion: Post-vaccination adverse effects were mild in all groups and controlled by analgesic. Fever, myalgia and pain at the injection site are the most common symptoms reported after vaccination by all three types of vaccines.

Short-term Safety of Covaxin, Sinopharm, Sputnik V, and AstraZeneca COVID-19 Vaccines Among Iranian Healthcare Workers: A Cross-Sectional Study

“…On the contrary, many findings from Pfizer and AstraZeneca vaccine studies showed that the prevalence of local and systemic side effects was higher among those who received the second dose than the first one (15-18). The immune system's ability, which functions more actively after the first dose of AstraZeneca, may explain the severity of side effects in this phase (19).…”

“…Since the emergence of the novel severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) in December 2019 as the causative agent of coronavirus disease 2019 (COVID- 19), a global pandemic has unfolded, significantly impacting healthcare systems worldwide (1). According to the World Health Organization (WHO), as of November 8, 2023, there have been 771 820 937 confirmed cases of COVID-19, resulting in 6 978 175 deaths (2).…”